Navco Pharmaceuticals Inc. NAV.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -62.07% | -48.84% | -67.39% | -95.71% | -96.76% |
| Depreciation & Amortization | -- | -- | -- | 100.00% | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -62.07% | -54.17% | -70.59% | -95.49% | -97.48% |
| Operating Income | 62.07% | 54.17% | 70.59% | 95.49% | 97.48% |
| Income Before Tax | 39.51% | 3.97% | 44.00% | 95.52% | 93.75% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 39.51% | 3.97% | 44.00% | 95.52% | 93.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 39.51% | 3.97% | 44.00% | 95.52% | 93.75% |
| EBIT | 62.07% | 54.17% | 70.59% | 95.49% | 97.48% |
| EBITDA | -- | -- | -- | 96.53% | 96.76% |
| EPS Basic | 0.00% | 0.00% | 0.00% | 95.58% | 95.65% |
| Normalized Basic EPS | 0.00% | 0.00% | 100.00% | 95.16% | 93.33% |
| EPS Diluted | 0.00% | 0.00% | 0.00% | 95.58% | 95.65% |
| Normalized Diluted EPS | 0.00% | 0.00% | 100.00% | 95.16% | 93.33% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | -0.06% | 2.98% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | -0.06% | 2.98% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |